Investment, Funding & Disinvestments

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

With a capacity exceeding 300 beds, the hospital will deliver both primary and secondary healthcare services to citizens and residents throughout the wilayat and surrounding areas.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

ADU-CRI operates through five specialized research divisions that target critical aspects of cancer care: Genomics and Bioinformatics Research, Biomarker Research, Drug Discovery and Development, Biosensors and Bioengineering, and Public Health Research.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.

This mission represented Mercy Ships’ fifth visit to Madagascar since 1996 and the second consecutive field service of the Africa Mercy in the port city of Tamatave.

This hub will enable closer collaboration with health authorities, clinicians, scientific associations, medical societies, and institutional partners throughout the Middle East and Africa.

The project will generate between 500 and 700 direct jobs and feature advanced digital infrastructure to ensure operational efficiency, traceability, and robust quality control.

Through this acquisition, Philips aims to enhance the precision and efficiency of coronary interventions, ultimately benefiting both healthcare professionals and patients.